Tbc2130 · Newsroom
OncoDxRx tests PGA on real-world patients, eyes drug response prediction technology leap
For the ‘lucky’ 2-3 in 10 patients who are eligible for precision medicine, the progression rate after first-line treatment is over 60%.April 16, 2025
OncoMRD: OncoDxRx's multi-spectral integrated gene panel for monitoring residual disease in solid tumor
Therapeutic surveillance of the patient is entrusted to OncoMRD (monitoring residual disease), a multi-spectral integrated gene panel that has been exclusively developed by OncoDxRx.April 4, 2025
OncoDxRx fortifies residual tumor monitoring arsenal amid rising cancer threats
OncoMRD represents a broader reaction at OncoDxRx to current and future theranostics developments.March 29, 2025
Unprecedented Drug Mapping Technology Provides Clues for Precision Treatment of Non-responders
A new way of selecting treatments for refractory cancer patients may have been uncovered by researchers at OncoDxRx.March 20, 2025
From Bench to Breakthrough: Translating Gene Signature into Life-Changing Therapies
The PGA solution is built on a solid foundation of experience and expertise, with no equivalent on the market.March 15, 2025
OncoDxRx to wield game-changing technologies in the fight of cancer
OncoDxRx doesn’t mince words when it comes to its ambitions: the company wants to dominate the precision theranostics field and punch through market boundaries.March 9, 2025
OncoDxRx's precision diagnostics innovations: efficiency, economy and personalization
The threats posed by cancer are intensifying, as witnessed by low patient response rates and frequent drug resistance in precision medicine.February 28, 2025
PGA vs. Biomarker Testing: Which Platform Reigns Supreme?
The PGA solution is built on a solid foundation of experience and expertise, with no equivalent on the market.February 22, 2025
Patient-Derived Gene Expression Signatures Are Pioneering Residual Tumor Monitoring
OncoMRD represents a generational shift in residual disease monitoring technology.February 14, 2025
OncoDxRx Responds to Growing Cancer Threat with Cutting-Edge Capabilities
As cancer threats evolve rapidly and high-intensity interventions resurface in clinic, OncoDxRx is accelerating the modernization of its precision theranostics and counter-cancer capabilities.February 11, 2025
OncoMRD: OncoDxRx Now Has One of Best Technology for Monitoring Residual Disease
OncoDxRx’s OncoMRD test impresses in late-stage cancer.February 1, 2025
OncoDxRx Draws Lessons from Precision Medicine to Address Modern Cancer Threats
Disruptive OncoDxRx technologies exclusively dedicated to the precision oncology domain.January 29, 2025
Improving patient treatment outcomes using cfmRNA-based OncoMRD analysis
Next-generation tumor biomarkers require broad coverage and depth, this “beyond tumor genome” necessity becomes even more pressing as clinicians face increasingly complex clinical situations.January 11, 2025
OncoDxRx Unveils a Decentralized Future for Personalized Medicine
A Vision for Advancing Patient Care Based on Personalized Gene SignatureJanuary 7, 2025
A responsibility to patients: close the biomarker testing gap in precision oncology
Gene-drug data is automatically or manually processed, according to content type, in order to extract maximum value to support clinical decision makers. PGA is able to map the gene signature to drug efficacy.December 24, 2024
Meet OncoDxRx's PGA: A 21st Century Technology Ahead Of Its Time
To understand the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) popularity, look at clinical utility - and turnaround time and costs.December 5, 2024
Gene Signature Could Predict Drug Response for Non-Small Cell Lung Cancer
Researchers at OncoDxR, have developed and validated a gene-to-drug technology that could enable earlier and faster identification of potentially effective drugs for patients with limited treatment options, using only small blood draws.November 19, 2024
OncoDxRx claims their new technology is most powerful to predict drug efficacy
PGA drug efficacy/response prediction: A range of options for non-responders.November 15, 2024
OncoDxRx Enters Molecular Residual Disease Market with Its Exclusive OncoMRD Test
OncoDxRx unveiled its proprietary OncoMRD assay for monitoring residual disease.November 11, 2024
Breakthrough Technology Predicts Drug Responses in People with Cancer
OncoDxRx researchers have invented a gene-to-drug mapping technology that can accurately predict drug efficacies among the existing 700+ cancer drugs and identify the best ones for people with cancer.November 3, 2024
OncoDxRx's blood test shows the benefits of drug efficacy prediction for non-responders
The clinical study found NSCLC patients whose treatment was guided by the PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) blood test had three times better clinical outcomes compared to patients that didn't.October 27, 2024
OncoDxRx’s PGA technology accurately predicted drug efficacy in non-responder patients
Researchers at OncoDxRx have invented a liquid biopsy technology, Patient-derived Gene expression-informed Anticancer drug efficacy (PGA), that can screen drug compounds to accurately predict efficacy in humans.October 20, 2024
Emphasis on off-label cancer treatment for non-responders is a must, OncoDxRx says
OncoDxRx is applying liquid biopsy, functional genomics and data science to reinvent and accelerate the process of drug repurposing and personalize off-label cancer treatment.October 11, 2024
OncoDxRx launches drug response prediction technology for therapeutic non-responders in world first
The precision genomics technology firm OncoDxRx used its exclusive digital mapping to link a patient’s gene expression signature to potentially effective cancer drugs, with the company dubbing the drug efficacy prediction test a world first.October 7, 2024
OncoDxRx to personalize off-label cancer drugs for patients who have run out of treatment options
Today, precision medicine is unevenly accessible for patients with advanced, refractory or relapsed cancers.September 18, 2024
New Technology Based on Gene Expression Could Identify Effective Drugs for Non-Responders in Cancer
Study finds patient-derived gene expression signature to be predictive of drug efficacy.September 7, 2024
One-Of-A-Kind Technology, PGA, Predicts Drug Response
Targeted therapy or immunotherapy has saved countless lives but only 20 to 30 percent of patients are eligible for the treatment. Predicting which drugs would benefit those non-responders could significantly help this desperate population.August 22, 2024
OncoDxRx aims to expand its exclusive liquid biopsy technology into monitoring residual disease
OncoDxRx, a California-based liquid biopsy startup, builds gene expression-powered treatment selection technology that helps clinicians identify the most suitable drugs for individual patients who are not responding to current therapies.August 18, 2024
PGA and OncoMRD technology breakthroughs, showing the teeth of OncoDxRx’s liquid biopsy umbrella
OncoDxRx integrates PGA drug response prediction and OncoMRD treatment monitoring capabilities.August 11, 2024
A Gene-to-Drug Renaissance
Liquid biopsy company OncoDxRx introduces its groundbreaking gene-to-drug mapping technology.August 3, 2024
PGA from OncoDxRx gives personalized cancer solutions
PGA offers drug recommendations and an action plan to the patient, outlining the best therapeutic implications and precision treatment.July 31, 2024
OncoDxRx Harnesses Tumor Gene Expression to Predict Drug Efficacy
There are many paths to cancer resistance; PGA technology can decode them simultaneouslyJuly 28, 2024
PGA drug response prediction with 360-degree Dx and Rx analytics
The broader the treatment options, the more it will benefit patients. This is why it is absolutely essential to ‘zoom out’ from targeted therapy, so patients are not overtaken by surprise when these precision treatments are exhausted.July 20, 2024
OncoDxRx Seeks 2024 IOC For Molecular Residual Disease Capability For Solid Tumor
OncoDxRx is expecting IOC of its one-of-a-kind MRD capability in 2024 with in vitro cfmRNA testing and in silico data computationJune 28, 2024
AI Isn’t the Magic Bullet to Simplify Drug Discovery
“Wet-lab patient testing and translational models are key to confirming AI-derived finding,” OncoDxRx said.June 11, 2024
OncoDxRx’s invisible battle to counter jamming from tumor cells
OncoDxRx leads scientific breakthrough that could revolutionize cancer treatment.June 3, 2024
PGA Technology Broadens and Quickens Precision Treatment Option for Unresponsive Cancer Patients
PGA is a revolutionary technology enabling drug response prediction that collects patient’s genetic signature data and performs real-time digital drug matching.May 23, 2024
Personalized cancer treatments based on PGA testing quickly leads to faster treatment, better outcomes
The breakthrough PGA technology enables us to analyze each patient’s data to better match them with tailored treatments and drug combinations.May 15, 2024
Reveal of OncoDxRx’s drug response prediction technology stirs up industry
At a time when healthcare resources are under pressure, the PGA technology allowing clinicians to select anticancer drugs at highest accuracy which will benefit the patient non-responders is really needed.April 7, 2024
Cancer treatment could be transformed by cutting-edge PGA technology
Every cancer is unique – different cancers require different treatments, and tumor evolution drives drug resistance, That’s why we need a better theranostics like PGA.March 24, 2024
PGA drug response prediction could help us to stay one step ahead of the disease
Early prediction of drug response based on pretreatment gene activity portraits (ie., gene expression signature) of cancer has become a necessity.March 21, 2024
PGA helps predict anticancer drug response in a week
Scientists at OncoDxRx leveraged gene expression profiles to tackle one of the biggest challenges facing oncology clinicians: drug response prediction for patient non-responders.March 18, 2024
Targeted gene expression signature paves the way for new cancer treatments
OncoDxRx scientists have developed a liquid biopsy-powered gene expression approach, to predict drug response and therapeutic outcome.March 10, 2024
Addressing Barriers to Implementing MRD Testing in Community Oncology Practices
Minimal residual disease (MRD) testing, like OncoDxRx's OncoMRD, appears to be a valuable tool for predicting outcomes and potential relapse in patients with cancer.March 5, 2024
Employing PGA to Optimize Treatment Selection
OncoDxRx’s PGA test provides access – the ability to find a way around. The one-of-a-kind technology can “re-measure the geometry of the tumor with regard to access to more therapeutic options”.February 28, 2024
Is lung cancer treatment working? This technology can tell from a blood draw
The OncoMRD (OncoDxRx’s molecular residual disease) test can capture and monitor tumor signals longitudinally in a patient's blood to determine how well a treatment is working in less than 5 days.February 19, 2024
Method that rapidly predicts drug efficacy clinically validated
Facing a variety of cancer threats from different directions, OncoDxRx recently launched a new gene-to-drug assay PGA that can provide rapid drug efficacy results to patients with limited treatment options.February 16, 2024
Potential New Lung Cancer Treatment Uncovered Using OncoDxRx’s PGA Platform
OncoDxRx has invented an exclusive liquid biopsy technology, PGA, for guiding drug discovery, development and repurposing, ultimately to create a more effective and safer therapeutic option for lung cancer patients.December 28, 2023
Innovations and Breakthroughs Shaping OncoDxRx's OncoMRD Technology
With the promise of saving millions of lives, OncoDxRx's OncoMRD is bornDecember 24, 2023